A Phase 3 interventional study of Fasinumab and Placebo in Chronic Low Back Pain and Osteoarthritis, sponsored by Regeneron Pharmaceuticals. Terminated at 56 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-30.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,029 studies in Osteoarthritis with a site in United States — 116 open to participants now, 175 under way, 14 of them phase 3. Osteoarthritis · United States.
Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 530th largest by enrollment of the 832 interventional ones that give a count, is one of 45 that started in 2017, is one of 128 in phase 3, and was the 693rd registered.
2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.
Browse Osteoarthritis studies →116 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
Columbia University · Sites in United States
Ages 18+
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,029 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 155 · Phase 3 143 · Phase 4 74
First in 1977; this study’s year is marked. 45 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 80 across 2,241 interventional studies indexed under Osteoarthritis.
Median enrollment 100 across the 832 interventional studies, 114 across the 188 observational. Of the 759 that completed or were terminated, 338 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
473 of 1,029 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 413 studies on the registry; 91 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 80 (63%) have results posted.
Regeneron Pharmaceuticals has 2 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
60 of the studies in Osteoarthritis with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06269705Phase 3Pacira Pharmaceuticals, IncZILRETTA in Subjects With Shoulder Osteoarthritis | 2026-12 |
| NCT05992883Phase 3Mayo ClinicNSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis | 2026-12-31 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT06003101Phase 3Massachusetts General HospitalEffect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies | 2027-08-30 |
Add all 60 to your calendar (.ics) → With an account.
Among the 1,029 studies in Osteoarthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the efficacy of fasinumab in relieving Chronic low back pain (CLBP) as compared to placebo in participants with a clinical diagnosis of moderate-to-severe non-radicular CLBP and Osteoarthritis (OA) of the knee or hip when treated for up to 16 weeks. The secondary objectives of the study are: To evaluate the safety and tolerability of fasinumab compared to placebo when participants with a clinical diagnosis of moderate-to-severe non-radicular CLBP and OA of the knee or hip are treated for up to 16 weeks; To characterize the concentrations of fasinumab in serum over time when participants with a clinical diagnosis of moderate-to-severe non-radicular CLBP and OA of the knee or hip are treated for up to 16 weeks; To evaluate the immunogenicity of fasinumab when treated for up to 16 weeks in participants with a clinical diagnosis of moderate-to-severe non-radicular CLBP and OA of the knee or hip.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/ Exclusion criteria apply.
Subcutaneous (SC) every 4 weeks (Q4W)
Drug: Fasinumab
SC every 4 weeks
Drug: Placebo
Subcutaneous (SC) every 4 weeks (Q4W)
Also known as: REGN475
Subcutaneous (SC) every 4 weeks (Q4W)
Change From Baseline to Week 16 in the Average Daily Low Back Pain Intensity (LBPI) Numeric Rating Scale (NRS) Score
Average daily low back pain (LBP) was assessed on an 11-point numeric rating scale (NRS) and was defined as the average of the non-missing daily LBPI NRS scores for the 7 days before and including nominal visit. Participants described their average low back pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate higher pain.
Time frame: Week 1, Week 2, Week 4, Week 8, Week 12, Week 16
Change From Baseline to Week 16 in the Roland Morris Disability Questionnaire (RMDQ) Total Score
The RMDQ is a self-administered, health status measure for lower back pain (LBP). It measures pain and function using 24 items describing limitations to everyday life that can be caused by LBP. The score of the RMDQ is the total number of items checked from a minimum of 0 (no disability) to a maximum of 24 (maximum disability), where lower scores are indicative of better function.
Time frame: Week 2, Week 4, Week 8, Week 12, Week 16
Change From Baseline to Week 16 in Patient Global Assessment (PGA) of Low Back Pain (LBP) Score
The PGA of LBP is a participant assessed 5 point Likert scale of LBP ranging from 1-5 where 1 = very well; 2 = well; 3 = fair; 4 = poor; and 5 = very poor.
Time frame: Week 2, Week 4, Week 8, Week 12, Week 16
Number of Participants Achieving ≥30% Reduction From Baseline to Week 16 in Average Daily LBPI NRS Score
Average daily low back pain (LBP) was assessed on an 11-point numeric rating scale (NRS) and was defined as the average of the non-missing daily LBPI NRS scores for the 7 days before and including nominal visit. Participants described their average low back pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate higher pain.
Time frame: Week 16
Change From Baseline to Week 16 in the Brief Pain Inventory-Short Form (BPI-sf) Pain Interference Score
The BPI-sf is a self-administered questionnaire for participants to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function. With a recall period of 24 hours, the questionnaire contains the front and back body diagrams, the 4 pain severity items and 7 pain interference items rated on 0-10 scale; total interference score ranges from 0-10 (0, does not interfere; 10 completely interferes), and the question about percentage of pain relief by analgesics. The BPI pain interference is typically scored as the mean of the 7 interference items.
Time frame: Week 2, Week 4, Week 8, Week 12, Week 16
Number of Adjudicated Arthropathy (AA) Events
Adjudicated arthropathy (AA) is a composite term that encompasses the following conditions: Rapidly progressive OA type 1 and 2, Subchondral insufficiency fractures, and Primary Osteonecrosis. AAs were also evaluated to determine if they met Destructive Arthropathy criteria.
Time frame: Up to Week 36
Number of Adjudicated Arthropathy (AA) Events Meeting Destructive Arthropathy (DA) Criteria
Destructive arthropathy (DA) is a unique clinical form of rapidly destructive arthropathy over and above that seen in the normal progression of OA. DA criteria can be associated with Rapidly Progressive Osteoarthritis type 2, Subchondral Insufficiency fracture, and Primary Osteonecrosis.
Time frame: Up to Week 36
Number of Treatment-Emergent Adverse Events (TEAEs)
Treatment-emergent adverse events (TEAEs) are defined as those that are not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period.
Time frame: Up to Week 16
Number of Sympathetic Nervous System (SNS) Dysfunction Events
Potential events of sympathetic nervous system (SNS) dysfunction were monitored throughout the study through physical examination, AE reporting, assessment of orthostatic hypotension, and the Survey of Autonomic Symptoms. Sympathetic nervous system dysfunction was diagnosed after consultation with an appropriate specialist, such as a neurologist and/or cardiologist.
Time frame: Up to Week 36
Number of Peripheral Sensory Adverse Events (AEs) That Require a Neurology Consultation
Any peripheral sensory AE (eg, paraesthesia and hypoaesthesia) that required a neurology consultation.
Time frame: Up to Week 36
Number of All-Cause Joint Replacement (JR) Surgery Events
All joint replacement surgery events regardless of cause.
Time frame: Up to Week 36
Number of Joint Replacement (JR) Surgery Events Reported at Telephone Survey After Last Dose of Study Drug
An end of study phone contact was conducted approximately 52 weeks following the last dose of study drug (week 12) to evaluate the number of participants who had undergone or were scheduled for JR surgery.
Time frame: Up to Week 64
Number of Participants With at Least One Positive Anti-Drug Antibody (ADA) Assay
Samples for Anti-Drug Antibody (ADA) evaluation were collected at baseline and at subsequent study visits. ADA variables include ADA status (+ or -) and titer as follows: Total participants negative in the ADA assay at all time points analyzed. Pre-existing immunoreactivity - positive response at baseline with all post-dose results negative, or a positive response at baseline with all post-dose responses less than 9-fold over baseline titer levels. Treatment emergent - post-dose positive result when baseline results were negative. Persistent - A positive result detected in at least 2 consecutive post baseline samples separated by at least a 16-week post baseline period, with no negative results in-between. Indeterminate - A positive result at the last collection time point analyzed only. Transient - Not persistent or indeterminate regardless of any missing samples. Treatment boosted - any post-dose positive result at least 9-fold over the baseline level when baseline is positive.
Time frame: 16 Weeks
Serum Concentration of Functional Fasinumab Over Time
Summary of mean concentration of functional fasinumab are presented by nominal time point.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 16
Participants were screened for study eligibility across the US. Of the 377 participants screened, 63 met eligibility criteria. The most frequently reported reason for non-randomization was inclusion criteria not met and/or exclusion criteria met (224 participants):139 did not meet inclusion criteria, 86 participants met exclusion criteria.
| Milestone | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Started | 32 | 31 |
| Completed | 19 | 27 |
| Not completed | 13 | 4 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 10 | 2 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Investigator/sponsor decision | 0 | 1 |
Average daily low back pain (LBP) was assessed on an 11-point numeric rating scale (NRS) and was defined as the average of the non-missing daily LBPI NRS scores for the 7 days before and including nominal visit. Participants described their average low back pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate higher pain.
| Score on a Scale | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Change from Baseline to Week 1 | -0.73 ± 1.424 | -1.62 ± 2.037 |
| Change from Baseline to Week 2 | -0.98 ± 1.588 | -2.15 ± 2.067 |
| Change from Baseline to Week 4 | -1.28 ± 1.878 | -2.64 ± 2.038 |
| Change from Baseline to Week 8 | -1.21 ± 1.568 | -2.82 ± 1.963 |
| Change from Baseline to Week 12 | -2.12 ± 1.582 | -3.18 ± 2.046 |
| Change from Baseline to Week 16 | -0.77 ± 1.943 | -2.32 ± 1.367 |
The RMDQ is a self-administered, health status measure for lower back pain (LBP). It measures pain and function using 24 items describing limitations to everyday life that can be caused by LBP. The score of the RMDQ is the total number of items checked from a minimum of 0 (no disability) to a maximum of 24 (maximum disability), where lower scores are indicative of better function.
| Score on a Scale | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Change from Baseline to Week 2 | -2.70 ± 5.120 | -2.54 ± 4.836 |
| Change from Baseline to Week 4 | -1.92 ± 4.529 | -3.09 ± 3.884 |
| Change from Baseline to Week 8 | 0.37 ± 4.487 | -4.18 ± 5.015 |
| Change from Baseline to Week 12 | 0.83 ± 3.061 | -3.33 ± 4.301 |
| Change from Baseline to Week 16 | -1.00 ± NA | -5.75 ± 3.948 |
The PGA of LBP is a participant assessed 5 point Likert scale of LBP ranging from 1-5 where 1 = very well; 2 = well; 3 = fair; 4 = poor; and 5 = very poor.
| Score on a Scale | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Change from Baseline to Week 2 | -0.44 ± 0.751 | -0.76 ± 0.786 |
| Change from Baseline to Week 4 | -0.60 ± 0.957 | -1.04 ± 0.676 |
| Change from Baseline to Week 8 | -0.55 ± 0.945 | -1.10 ± 1.021 |
| Change from Baseline to Week 12 | -0.57 ± 1.134 | -1.00 ± 1.333 |
| Change from Baseline to Week 16 | 0.00 ± NA | -0.75 ± 0.500 |
Average daily low back pain (LBP) was assessed on an 11-point numeric rating scale (NRS) and was defined as the average of the non-missing daily LBPI NRS scores for the 7 days before and including nominal visit. Participants described their average low back pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate higher pain.
| Participants | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Number of Participants Achieving ≥30% Reduction From Baseline to Week 16 in Average Daily LBPI NRS Score | 12 | 21 |
The BPI-sf is a self-administered questionnaire for participants to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function. With a recall period of 24 hours, the questionnaire contains the front and back body diagrams, the 4 pain severity items and 7 pain interference items rated on 0-10 scale; total interference score ranges from 0-10 (0, does not interfere; 10 completely interferes), and the question about percentage of pain relief by analgesics. The BPI pain interference is typically scored as the mean of the 7 interference items.
| Score on a Scale | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Change from Baseline to Week 2 | -1.55 ± 2.306 | -1.94 ± 2.255 |
| Change from Baseline to Week 4 | -1.49 ± 2.390 | -2.15 ± 2.157 |
| Change from Baseline to Week 8 | -1.31 ± 2.119 | -2.70 ± 2.774 |
| Change from Baseline to Week 12 | -1.63 ± 2.096 | -1.84 ± 1.978 |
| Change from Baseline to Week 16 | -1.14 ± NA | -1.29 ± 3.017 |
Adjudicated arthropathy (AA) is a composite term that encompasses the following conditions: Rapidly progressive OA type 1 and 2, Subchondral insufficiency fractures, and Primary Osteonecrosis. AAs were also evaluated to determine if they met Destructive Arthropathy criteria.
| Adjudicated Arthropathy (AA) Events | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Number of Adjudicated Arthropathy (AA) Events | 0 | 2 |
Destructive arthropathy (DA) is a unique clinical form of rapidly destructive arthropathy over and above that seen in the normal progression of OA. DA criteria can be associated with Rapidly Progressive Osteoarthritis type 2, Subchondral Insufficiency fracture, and Primary Osteonecrosis.
| Destructive Arthropathy (DA) Events | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Number of Adjudicated Arthropathy (AA) Events Meeting Destructive Arthropathy (DA) Criteria | 0 | 0 |
Treatment-emergent adverse events (TEAEs) are defined as those that are not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period.
| Treatment-Emergent Adverse Events | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Number of Treatment-Emergent Adverse Events (TEAEs) | 33 | 14 |
Potential events of sympathetic nervous system (SNS) dysfunction were monitored throughout the study through physical examination, AE reporting, assessment of orthostatic hypotension, and the Survey of Autonomic Symptoms. Sympathetic nervous system dysfunction was diagnosed after consultation with an appropriate specialist, such as a neurologist and/or cardiologist.
| Sympathetic NS Dysfunction Events | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Number of Sympathetic Nervous System (SNS) Dysfunction Events | 0 | 0 |
Any peripheral sensory AE (eg, paraesthesia and hypoaesthesia) that required a neurology consultation.
| Peripheral Sensory Adverse Events (AEs) | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Hypoaesthesia events | 1 | 0 |
| Paraesthesia events | 1 | 0 |
All joint replacement surgery events regardless of cause.
| Joint Replacement (JR) Surgery Events | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Number of All-Cause Joint Replacement (JR) Surgery Events | 2 | 1 |
An end of study phone contact was conducted approximately 52 weeks following the last dose of study drug (week 12) to evaluate the number of participants who had undergone or were scheduled for JR surgery.
| Joint Replacement (JR) Surgery Events | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Number of Joint Replacement (JR) Surgery Events Reported at Telephone Survey After Last Dose of Study Drug | 0 | 0 |
Samples for Anti-Drug Antibody (ADA) evaluation were collected at baseline and at subsequent study visits. ADA variables include ADA status (+ or -) and titer as follows: Total participants negative in the ADA assay at all time points analyzed. Pre-existing immunoreactivity - positive response at baseline with all post-dose results negative, or a positive response at baseline with all post-dose responses less than 9-fold over baseline titer levels. Treatment emergent - post-dose positive result when baseline results were negative. Persistent - A positive result detected in at least 2 consecutive post baseline samples separated by at least a 16-week post baseline period, with no negative results in-between. Indeterminate - A positive result at the last collection time point analyzed only. Transient - Not persistent or indeterminate regardless of any missing samples. Treatment boosted - any post-dose positive result at least 9-fold over the baseline level when baseline is positive.
| Participants | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Negative/Pre-Existing | 31 | 31 |
| Treatment Boosted | 0 | 0 |
| Treatment-Emergent | 0 | 0 |
| Treatment-Emergent: Persistent | 0 | 0 |
| Treatment-Emergent: Transient | 0 | 0 |
| Treatment-Emergent: Indeterminate | 0 | 0 |
Summary of mean concentration of functional fasinumab are presented by nominal time point.
| Milligram per Liter (mg/L) | Fasinumab 3 mg SC Q4W |
|---|---|
| Baseline | 0 ± 0 |
| Week 2 | 0.262 ± 0.0992 |
| Week 4 | 0.176 ± 0.0679 |
| Week 8 | 0.247 ± 0.130 |
| Week 16 | 0.192 ± 0.0932 |
Collected over From the first dose of study drug up to 24 weeks post the last dose of study drug (up to week 36). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fasinumab-matching Placebo | 0/32 (0%) | 1/32 (3.1%) | 14/32 (43.8%) |
| Fasinumab 3 mg SC Q4W | 0/31 (0%) | 2/31 (6.5%) | 4/31 (12.9%) |
| Event | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Breast cancer stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/32 | 1/31 |
| DizzinessNervous system disorders | 0/32 | 1/31 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/32 | 1/31 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/32 | 0/31 |
| Event | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 5/32 | 0/31 |
| Upper respiratory tract infectionInfections and infestations | 4/32 | 1/31 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/32 | 3/31 |
| Blood creatine phosphokinase increasedInvestigations | 3/32 | 1/31 |
| Neck PainMusculoskeletal and connective tissue disorders | 2/32 | 1/31 |
| Peripheral swellingGeneral disorders | 2/32 | 0/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/32 | 0/31 |
| Age, Continuous(years) | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W | Total |
|---|---|---|---|
| Mean | 57.7 ± 9.88 | 60.0 ± 10.52 | 58.8 ± 10.18 |
| Sex: Female, Male(Participants) | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W | Total |
|---|---|---|---|
| Female | 21 | 18 | 39 |
| Male | 11 | 13 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 4 |
| Not Hispanic or Latino | 31 | 28 | 59 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W | Total |
|---|---|---|---|
| White | 15 | 17 | 32 |
| Black or African American | 15 | 14 | 29 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Average Daily Low Back Pain Intensity (LBPI) Numerical Rating Scale (NRS) Score(Score on a Scale) | Fasinumab-matching Placebo | Fasinumab 3 mg SC Q4W | Total |
|---|---|---|---|
| Mean | 6.66 ± 1.475 | 6.81 ± 1.338 | 6.73 ± 1.400 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in May 2018, 6 months.
Results were first posted in Jun 2021, 3 years 1 month after primary completion. A results delay was requested in Apr 2019.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fasinumab